You are currently browsing the archives for 22 July 2018.
Displaying 1 entry.

A subsidiary of CSL Limited.

That supply is manufactured in Australia. Nearly all that delivery shall be in thimerosal-free, prefilled syringes. CSL Biotherapies lately signed an initial contract for at least $180 million to provide the U.S. Division of Health & Human Services with Novel Influenza A antigen. Licensure of the brand new facility in Kankakee provides CSL Biotherapies with the ability to fill and bundle that antigen if requested to do so by HHS.S.S. Public health needs. It also underscores our support to enhance vaccine administration safety by using ready-to-use prefilled syringes. At full capability, 20 million doses in thimerosal-free prefilled syringes shall be filled and packaged at the Illinois-based site.